Exicure Inc (XCUR) Stock Price, Quote & News

Company Profile

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 847 673 1700

Website: www.exicuretx.com

Address:

400 Seaport Court, Suite 102, Redwood City, United States

Mantraset3 Jun. 22 at 8:44 AM

$XCUR umm hello ?

1 · Reply

AnalyticaInvestor Jun. 11 at 10:15 AM

$KEQU $XCUR $TECX $HUMA Good morning, investors. Rising tensions surrounding Iran are pushing energy prices higher and adding another layer of volatility to markets. Attention now turns to inflation data, Federal Reserve expectations, and upcoming earnings reports. Rising input costs remain a key concern, particularly for companies with weaker pricing power and tighter margins. Read the full Analytica Alpha 👇 https://analyticainvestor.beehiiv.com/p/hot-cpi-iran-risk-selloff

0 · Reply

NVDAMillionaire Jun. 10 at 8:22 AM

$XCUR Outstanding article that hits the mark on XCUR's current state. So if you want to refresh your XCUR insights or learn about XCUR from scratch, this is a must read. https://everyticker.com/quote/XCUR/analysis/exicure-s-3-16-gamble-a-dying-biotech-s-last-shot-at-redemption-through-gpcr-s-phase-2-asset-nasdaq-xcur

0 · Reply

Bidzill May. 27 at 11:22 AM

$XCUR

1 · Reply

SuperGreenToday May. 26 at 9:14 PM

$XCUR

0 · Reply

Red2Profit Apr. 23 at 8:51 AM

$XCUR Daily double bottom neckline at 9.49. 4 Hour falling wedge. Let's break 4.25 and 5.07 and we'll be on our way

0 · Reply

AlertsAndNews Apr. 23 at 2:36 AM

$XCUR headline here right into the AH close Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

0 · Reply

topstockalerts Apr. 23 at 1:42 AM

After Hours Top Gainers $MEHA $AKAN $TOMZ $QS $XCUR

0 · Reply

JLCw Apr. 23 at 12:44 AM

Watchlist – Thursday April 23 Names holding near highs with catalysts and clear levels. Looking for continuation if volume shows back up $XCUR strong close and reclaim over 4 with a tight float and insider ownership behind it. Needs follow through over 4.25 to open the next leg. $SHFS low float cannabis fintech name holding around 1.00 after the move. Recent headlines keeping it active. Watching for volume through 1.10 $YCBD ran from 0.80-1.20s and holding up so far. Sector attention helping and insider activity adds interest. Needs 1.25 to continue $LHSW heavy volume and held the move well. Sitting right under 0.29 with insider activity and contract headline in the background. Needs that push to open it up $PAPL buyback catalyst behind the move and holding near highs after running from the 0.60s. Watching for continuation through 0.95 JL

0 · Reply

islandpunk Apr. 23 at 12:19 AM

$XCUR https://www.stocktitan.net/news/XCUR/exicure-announces-co-development-agreement-with-adbiotech-for-9af2860at4i6.html

0 · Reply

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

2026-06-01T20:21:37.000Z - 27 days ago

Exicure receives noncompliance notification from Nasdaq

Jun 1, 2026, 4:00 PM EDT - 27 days ago

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Apr 22, 2026, 7:54 PM EDT - 2 months ago

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Apr 2, 2026, 4:01 PM EDT - 3 months ago

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Mar 25, 2026, 4:18 PM EDT - 3 months ago

Exicure, Inc. Reports Full Year 2025 Financial Results

2026-02-05T12:11:02.000Z - 5 months ago

Exicure announces publication of results from Phase 2 study of burixafor

Feb 5, 2026, 7:00 AM EST - 5 months ago

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

2026-01-21T12:15:40.000Z - 5 months ago

Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings

Jan 21, 2026, 7:00 AM EST - 5 months ago

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

2025-12-08T21:40:59.000Z - 7 months ago

Exicure presents topline data from burixafor combination trial

Dec 8, 2025, 4:30 PM EST - 7 months ago

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

2025-12-05T16:05:28.000Z - 7 months ago

Exicure Inc trading resumes

2025-12-05T16:00:37.000Z - 7 months ago

Exicure Inc trading halted, volatility trading pause

Nov 7, 2025, 4:00 PM EST - 8 months ago

Exicure, Inc. Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:00 AM EST - 8 months ago

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Oct 22, 2025, 4:15 PM EDT - 8 months ago

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

2025-10-06T11:30:52.000Z - 9 months ago

Exicure appoints Josephine Cardarelli as president, CSO

BMY

2025-10-06T11:25:17.000Z - 9 months ago

Exicure announces near-term strategic priorities

Oct 6, 2025, 7:00 AM EDT - 9 months ago

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Aug 8, 2025, 4:01 PM EDT - 11 months ago

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 4:37 PM EDT - 11 months ago

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

2025-08-01T20:05:21.000Z - 11 months ago

Exicure completes last patient in Phase 2 GPC-100 combo trial

Aug 1, 2025, 4:01 PM EDT - 11 months ago

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

2025-07-14T15:51:17.000Z - 1 year ago

Exicure files to sell 5.16M shares of common stock for holders

2025-07-03T14:25:23.000Z - 1 year ago

Exicure Inc trading resumes

2025-07-03T14:15:16.000Z - 1 year ago

Exicure Inc trading halted, volatility trading pause

2025-07-01T01:06:00.000Z - 1 year ago

Is Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?

Jun 27, 2025, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports First Quarter 2025 Financial Results

2025-05-28T21:00:13.000Z - 1 year ago

Exicure receives Nasdaq delinquency notice on late Form 10-Q filing

May 28, 2025, 4:58 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

2025-05-05T13:26:04.000Z - 1 year ago

Exicure completes patient enrollment in GPC-100 trial

May 5, 2025, 8:00 AM EDT - 1 year ago

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Apr 14, 2025, 6:11 PM EDT - 1 year ago

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Apr 11, 2025, 7:42 PM EDT - 1 year ago

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

2025-03-18T20:16:39.000Z - 1 year ago

Exicure reports FY24 EPS ($4.75) vs. ($10.55) last year

Mar 18, 2025, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Full Year 2024 Financial Results

2025-03-13T20:10:26.000Z - 1 year ago

Exicure announces issuance of new patent in Australia

Mar 13, 2025, 4:08 PM EDT - 1 year ago

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Jan 23, 2025, 12:17 AM EST - 1 year ago

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 22, 2025, 4:01 PM EST - 1 year ago

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Dec 26, 2024, 8:08 PM EST - 1 year ago

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Dec 21, 2024, 1:48 PM EST - 1 year ago

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 20, 2024, 4:42 PM EST - 1 year ago

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Nov 14, 2024, 4:01 PM EST - 1 year ago

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Sep 18, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Aug 26, 2024, 9:08 AM EDT - 2 years ago

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Aug 19, 2024, 10:31 AM EDT - 2 years ago

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 15, 2024, 10:31 AM EDT - 2 years ago

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 13, 2024, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:27 PM EDT - 2 years ago

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Aug 1, 2024, 4:01 PM EDT - 2 years ago

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Jun 17, 2024, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports First Quarter 2024 Financial Results

Jun 6, 2024, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Full Year 2023 Financial Results

May 23, 2024, 4:01 PM EDT - 2 years ago

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

May 16, 2024, 4:08 PM EDT - 2 years ago

Exicure, Inc. Reports Third Quarter 2023 Financial Results

Apr 22, 2024, 4:01 PM EDT - 2 years ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Feb 5, 2024, 4:01 PM EST - 2 years ago

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Aug 23, 2023, 9:48 AM EDT - 3 years ago

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Aug 11, 2023, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 14, 2023, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 26, 2023, 4:01 PM EDT - 3 years ago

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

May 4, 2023, 4:01 PM EDT - 3 years ago

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Mar 27, 2023, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 5:10 PM EST - 3 years ago

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Dec 14, 2022, 5:00 AM EST - 3 years ago

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Nov 14, 2022, 4:01 PM EST - 3 years ago

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Mantraset3 Jun. 22 at 8:44 AM

$XCUR umm hello ?

1 · Reply

AnalyticaInvestor Jun. 11 at 10:15 AM

0 · Reply

NVDAMillionaire Jun. 10 at 8:22 AM

0 · Reply

Bidzill May. 27 at 11:22 AM

$XCUR

1 · Reply

SuperGreenToday May. 26 at 9:14 PM

$XCUR

0 · Reply

Red2Profit Apr. 23 at 8:51 AM

$XCUR Daily double bottom neckline at 9.49. 4 Hour falling wedge. Let's break 4.25 and 5.07 and we'll be on our way

0 · Reply

AlertsAndNews Apr. 23 at 2:36 AM

$XCUR headline here right into the AH close Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

0 · Reply

topstockalerts Apr. 23 at 1:42 AM

After Hours Top Gainers $MEHA $AKAN $TOMZ $QS $XCUR

0 · Reply

JLCw Apr. 23 at 12:44 AM

0 · Reply

islandpunk Apr. 23 at 12:19 AM

$XCUR https://www.stocktitan.net/news/XCUR/exicure-announces-co-development-agreement-with-adbiotech-for-9af2860at4i6.html

0 · Reply

focafoca99 Apr. 11 at 9:08 PM

$XCUR added Yoontae Han to the board and audit committee and appointed Young Seung Ko as chief operating officer.

0 · Reply

focafoca99 Apr. 3 at 8:35 PM

$XCUR says a federal court preliminarily approved the settlement of its stockholder derivative cases, with a final hearing set for June 2.

0 · Reply

OatesTheGoat Mar. 20 at 1:48 PM

$XCUR 9/48 EMA cross today on the daily chart

0 · Reply

topstockalerts Mar. 20 at 12:56 PM

$XCUR super thin and unpredictable. If volume hits, it can overshoot levels before anyone adjusts.

0 · Reply

hegdaom Mar. 19 at 10:13 PM

$XCUR New basing pattern towards 5-7 over next days for resistance

0 · Reply

kshonstocks Mar. 19 at 9:49 PM

This little $XCUR interesting, trying to come out of a sort of base

1 · Reply

hegdaom Mar. 19 at 7:45 PM

$XCUR Very little volume will take this puppy above 9-10$ in no time.

0 · Reply

hegdaom Mar. 19 at 5:02 PM

$XCUR Interesting pattern brewing here. looks like above 5 soon and 6 shortly.

0 · Reply

hegdaom Mar. 18 at 12:01 AM

$XCUR

0 · Reply

ripztrip Mar. 17 at 9:47 PM

$XCUR

0 · Reply

Market Cap	15.30M
Revenue (ttm)	0.00
Net Income (ttm)	-4.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	68,900
Avg Vol	25,804
Day's Range	N/A - N/A
Shares Out	6.37M
Stochastic %K	46%
Beta	3.53
Analysts	Strong Buy
Price Target	$2.00